$35.13
3.81% today
Nasdaq, Feb 28, 05:19 pm CET
ISIN
US92337F1075
Symbol
VCYT
Sector
Industry

Veracyte Inc Stock price

$33.84
-9.09 21.17% 1M
+1.84 5.75% 6M
-5.76 14.55% YTD
+10.22 43.27% 1Y
+6.04 21.73% 3Y
+10.02 42.07% 5Y
+25.05 284.98% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-1.69 4.76%
ISIN
US92337F1075
Symbol
VCYT
Sector
Industry

Key metrics

Market capitalization $2.62b
Enterprise Value $2.38b
P/E (TTM) P/E ratio 111.87
EV/FCF (TTM) EV/FCF 37.36
EV/Sales (TTM) EV/Sales 5.35
P/S ratio (TTM) P/S ratio 5.88
P/B ratio (TTM) P/B ratio 2.23
Revenue growth (TTM) Revenue growth 23.46%
Revenue (TTM) Revenue $445.76m
EBIT (operating result TTM) EBIT $23.73m
Free Cash Flow (TTM) Free Cash Flow $63.81m
Cash position $289.44m
EPS (TTM) EPS $0.30
P/E forward 74.92
P/S forward 5.36
EV/Sales forward 4.87
Short interest 4.51%
Show more

Is Veracyte Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Veracyte Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Veracyte Inc forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a Veracyte Inc forecast:

Buy
82%
Hold
18%

Financial data from Veracyte Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
446 446
23% 23%
100%
- Direct Costs 151 151
10% 10%
34%
312 312
40% 40%
70%
- Selling and Administrative Expenses 202 202
36% 36%
45%
- Research and Development Expense 68 68
21% 21%
15%
47 47
169% 169%
11%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 24 24
304% 304%
5%
Net Profit 24 24
132% 132%
5%

In millions USD.

Don't miss a Thing! We will send you all news about Veracyte Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Veracyte Inc Stock News

Neutral
Seeking Alpha
3 days ago
Veracyte, Inc. shows strong revenue growth and market share in genomic diagnostics, particularly with its Decipher and Afirma tests, but faces significant near-term challenges. 2024 ended positively with 23% revenue growth and strong cash flow, yet 2025 will be critical for transitioning to a stable, profit-generating leader. Regulatory uncertainties, Afirma's growth deceleration, and potential...
Neutral
Seeking Alpha
4 days ago
Veracyte, Inc. (NASDAQ:VCYT ) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Shayla Gorman - Senior Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research, LLC Mason Carrico - Stephens Inc. Puneet Souda - Leerink Partners Maggie Boeye - Willia...
Neutral
Business Wire
4 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2024. “I'm incredibly proud of what our team accomplished in 2024,” said Marc Stapley, Veracyte's chief executive officer. “We ended the year with exceptional performance, delivering record revenue in Q4 and achieving our 10th cons...
More Veracyte Inc News

Company Profile

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Head office United States
CEO Marc Stapley
Founded 2006
Website www.veracyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today